G.V. Prasad

G.V. Prasad has led Dr. Reddy's Laboratories for over two decades, building on the legacy of founder Dr. Anji Reddy (his father-in-law) who started the company in 1984 in Hyderabad. Dr. Reddy's has grown into one of India's most globally recognized pharmaceutical companies, manufacturing and marketing generic drugs, biosimilars, and active pharmaceutical ingredients across more than 60 countries. Dr. Reddy's portfolio spans multiple therapeutic areas including oncology, gastroenterology, cardiovascular, and dermatology. The company has been investing in complex generics (difficult-to-make formulations that face less competition and command higher margins), biosimilars (which provide affordable alternatives to expensive biologic drugs), and innovative drug development through its proprietary products pipeline. The North American market (primarily the U.S.) is the largest revenue contributor, followed by India, Europe, and emerging markets. Prasad has navigated the company through regulatory challenges (FDA inspections of Indian manufacturing facilities are a perennial risk) and the pressure of declining generic drug prices in the U.S. Key stock drivers include U.S. generic drug pricing trends, biosimilar launches and market share, complex generic approvals, regulatory inspection outcomes, Indian domestic market growth, API business performance, and the competitive dynamics within India's crowded pharmaceutical sector.